CN Bio Licenses Human Gut Microbiome Modeling Tool from MIT and Northeastern University; Tool Expected to Enable New Insights on Relationship Between Human Microbiome and Effects on Human Health

On July 27, 2027, CN Bio, a leading Organ-on-a-Chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), announced it has secured the licensing rights to a novel tool for modelling the gut microbiome (GuMI), from Massachusetts Institute of Technology (MIT) and Northeastern University. Planned for commercial launch in 2023, the technology will be integrated into CN Bio’s PhysioMimix OOC range of single- and multi-organ MPS, enabling researchers to investigate the direct interaction between the microbiome and gut, and the wider effects of the microbiome on organs such as the liver and brain.